BREXPIPRAZOLE: A NEW DOPAMINE D2 RECEPTOR PARTIAL AGONIST FOR THE TREATMENT OF SCHIZOPHRENIA AND MAJOR DEPRESSIVE DISORDER
BREXPIPRAZOLE: A NEW DOPAMINE D2 RECEPTOR PARTIAL AGONIST FOR THE TREATMENT OF SCHIZOPHRENIA AND MAJOR DEPRESSIVE DISORDER
复制标题
DOI：
10.1358/dot.2015.51.7.2358605
复制
发表时间：
2015-07-01
期刊：
影响因子：
1.8
通讯作者：
Citrome, L.
中科院分区：
文献类型：
--
作者：
Citrome, L.
Please try later.
Brexpiprazole is a dopamine D-2 receptor partial agonist. Compared with aripiprazole, it is more potent at 5-HT1A receptors and displays less intrinsic activity at D-2 receptors. Brexpiprazole also has potent antagonistic activity at observed for placebo. Although overall akathisia was more commonly observed with brexpiprazole than with placebo, the absolute risk increase attributable to brexpiprazole appears small. Short-term weight gain appears modest; however, outliers with an increase of >= 7% of body weight were evident in open-label long-term safety studies.